This article was originally published on TipRanks.com Incyte (INCY) is an American multinational drug developer.
This article was originally published on TipRanks.com Biopharmaceutical company Incyte (NASDAQ: INCY) announced that the U.
Incyte announced that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of its ruxolitinib …
Incyte (INCY) and MorphoSys (MOR) have announced that the US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) plus lenalidomide for adults with relapsed …
Incyte (INCY) has reported 1Q20 EPS that included a 22% year-over-year rise in blood cancer drug Jakafi to $460 million, above consensus of …
Incyte (INCY) has announced that the FDA has approved Pemazyre, a kinase inhibitor for the treatment of adults with unresectable cholangiocarcinoma, a rare cancer …
Global biotech company Incyte (INCY) announced on Friday that it has initiated a Phase 3 clinical trial in collaboration with Novartis (NVS) to …
Global biopharma Incyte (INCY) has announced plans to initiate a Phase 3 clinical trial to evaluate cancer drug Jakafi in patients with COVID-19 …
By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …
This morning, Incyte (NASDAQ:INCY) announced that the company’s ECHO-301 study comparing epacadostat in combination with pembrolizumab with pembrolizumab alone in melanoma failed to …
